On February 13, 2020, a group of post-docs from the University of Wisconsin – Madison had the opportunity to spend a day at the Promega headquarters in Fitchburg, WI. Throughout the day, the group heard from a list of speakers including Tom Livelli, VP of Life Sciences, and representatives from Technical Services, Sales, R&D and Marketing. The day concluded with a tour of the Feynman Manufacturing Center, where attendees saw production and packing lines, as well as training and QC labs.
On February 13, 2020, a group of post-docs from the
University of Wisconsin – Madison had the opportunity to spend a day at the
Promega headquarters in Fitchburg, WI. Throughout the day, the group heard from
a list of speakers including Tom Livelli, VP of Life Sciences, and
representatives from Technical Services, Sales, R&D and Marketing. The day
concluded with a tour of the Feynman Manufacturing Center, where attendees saw
production and packing lines, as well as training and QC labs.
“It’s always encouraging as a scientist to hear about how
each person is different and how they’ve had different twists and turns,” says Alexa
Heaton, a post-doc studying immunotherapy interactions in mice. “It’s great to
hear from such a range of people and the different job types I could consider.”
To recap the day, we’ve captured a few of the biggest
Building a successful career in the biotechnology industry
is really just a series of transitions from one role to another. But the devil
is in the details—when to make a change, how to create opportunities and who
can be your champion as you pivot. So how do you navigate these factors to keep
your career goals on course?
I recently attended a symposium (presented by the University of Wisconsin Master of Science in Biotechnology Program, of which I’m an alum) that addressed this topic through the lens of one individual with a storied career in the industry. Bob Weiland currently serves on the Board of Directors for CymaBay Therapeutics. He has held various roles, from sales and marketing to operations and strategy, within large, established companies (Abbot, Baxter, Takeda) and smaller ones (Pacira Pharmacueticals). He drew on this wide-ranging experience to provide advice to professionals at all career stages.
Bob began the talk by declaring that there will be points in
your career when you reach a “hard spot” and will need to transition, whether
to a new role, company or even industry, to meet your career goals. He
suggested a good starting point is simply to be thinking about making a change.
But in the same breath he emphasized, “What are you doing about it?” He
identified four distinct actions that you can take to ensure role changes and
career transitions support your professional growth and development.
A recent PNAS article tracked the careers of
scientists in three different fields based on research paper authorship. They
found that, over a 50-year span, there was a dramatic reduction in how long
scientists remained in each field, which they termed “survivability.” More than
half of the scientists that started out in the 1960s published in their field
for an average of 35 years, while about half of scientists starting in the
2010s published in their field for an average of 5 years1. Tracked academic
researchers were classified into three categories: transients (authors who had
only one publication during their career), dropouts (authors who stopped
publishing at various career levels), and full-career scientists (authors who continue
to publish in the field). Overall, the data showed that there are an increasing
number of transients that contribute to scientific papers. Thus, the authors of
the PNAS article concluded that the demographics
in those academic fields are shifting toward scientists who leave the field
quickly. The observed increase in the number of scientists who are temporarily
in academia makes sense, given the number of PhDs relative to the limited
number of faculty positions and permanent staff scientist roles. However, the
terms “survivability,” “transients,” and “dropouts” give the impression that
leaving academia means that these scientists have ended their career or failed.
It can be easy to forget that Promega is a manufacturing business. Hidden within the well-designed walls of the company’s cGMP Feynman Center, as well as in other facilities on the Madison campus, technicians operate hundreds of machines that manufacture, dispense and package Promega reagents day in and day out. Keeping those high-tech machines running at peak performance is critical, requiring immense skill, precision and even artistry. That’s where Promega Machinist Technician Travis Beyer comes in.
“I get to make stuff,” says Travis who is not afraid to show his enthusiasm for his craft while describing the best part of his job. “There’s a product at the end of the day. Plus I get to support science, and make things that support people’s lives. That’s cool.”
I get to make stuff. There’s a product at the end of the day. Plus I get to support science, and make things that support people’s lives. That’s cool.
The da Vinci Center, another artfully designed building on the Madison campus, houses the Promega machine shop where Travis does his work designing or improving on parts for newer manufacturing equipment or reverse engineering broken or worn parts no longer available for older equipment that still serves its purpose. He makes every machine part imaginable from drive shafts to sensor brackets to filling forks, and his work is critical to manufacturing businesses like Promega, where a downed piece of equipment can cause costly production delays.